 4D pharma PLC AIM:DDD, NASDAQ:LBPS will deliver whats called a trial in progress poster at a world-leading cancer conference outlining the plans and aims of a phase II study of its cancer drug candidate used alongside an immune checkpoint inhibitor drug. Delegates at the American Society of Clinical Oncology meeting in Chicago will be told that MRx0518 will be coupled with Bavencio to treat a common form of bladder cancer. 